Inn er ear barotrauma am ong scuba divers is believed to be caused by any ofthr ee conditions: a hemorrhage in the inner ear, a tear of the laby rinthine membrane, or a perilymphatic fi stula . These injuries may occur con currently or separately. Hem orrh age and membrane rupture are managed conse rvatively, while fistula requires surgical repair.
Introduction
There are an estimated 3 to 10 million recreational scuba (for "self-contained unde rwater breathing apparatus") dive rs in the United State s. Therefore, a significant number of persons are at risk of experiencing barotrauma to the ear, a condition that was first reported by Eichel and Landes in 1970. 1 In fact , middl e ear barotrauma is the most common malady that affects divers.' It is the result of the imb alance in pressure between the external environm ent and the middle ear during a diver ' s descent.
Middl e ear barotrauma usually resolves naturally and without sequelae. On the other hand, inner ear barotrauma, although it is rare, is potenti ally more serious . Its se-quelae-which include cochleovestibular symptoms of tinnitus , fullness, sensorineural hearing loss, dizziness, and vertigo-may be perm anent and disabling. Either one of these conditions may occur in as little as 8 feet of water.' The reason that these injuri es can occur at such shallow depths is explained by Boyle' s law, which states that there is an inverse relationship between volume and pressure . For a diver, every 33 feet of seawater depth puts one addition al atmos phere of pressure on the body. By contr ast, a person would have to climb to 18,000 feet of altitude to experience a decre ase of ju st one-half an atmosphere.
Mo st patients who have suffered inner ear barotraum a have been coun seled against further partic ipation in scuba diving. However, this recommendation is based on an unsub stantiated theor y which holds that a previou sly injured inner ear is at increased risk for further injury . More recent reports in the literature now suggest that the se patients may resume diving safely after appropriate therapy. The purpose of this paper is to revi ew the etiology and treatment of inner ear barotrauma and to describe the cases of3 patients who suffered inner ear barotrauma. One of these patients was able to resume di ving without further sequelae. The other 2 patient s suffered perilymphatic fistula secondary to inner ear barot raum a and have abandoned diving. , and Streptococcus pyogenes* . Pharyngitis and Tonsittitis, caused by S. pyogenes. Note: Peni cillin is the usual drug of choice in the treatment of S. pyogenes infection s, inciuding the prophylaxis of rheumatic fever. SUPRAX is generally effective in the eradication of S. pyogenes from the nasopharynx; however, dataestablishi ng theefficacy of SUPRAXin the subsequent prevention of rheumatic fever are not available. Uncomplicated Urinary Tract Infections caused by Escherichia coli and Proteus mirabitis. Uncomplicated gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase-and nonpenicillinase-producing strains). Appropriate cultures and susceptibility studies shouid be performed to determ ine the causati ve organi sm and its susce ptibility to SUPRAX; however, therapy may bestarted whileawaitingthe result s of these studies. Therapy should beadjusted, if necessary, oncethese resulls are known.
*Efficacy for this organismin this organsystem was studied in fewerthan10 infections.
CONTRAINOICATIONS:
In pati ents with knownallergyto thecephalosporin group of antibiotics. Administer antibiotics, including SUPRAX, cautiously to anypatient who has demonstrated some form of allergy, parti cul arl y to drugs. Treatmentwith broad -spectrum antibiotics, including SUPRAX, alters the normai flora of the colon ahd may perm it ove rgrowth of clostridia.'Studies indicate that a toxin produced by Cl ostridium difficile is a primary . cause of severeantibiotic-associated diarrhea including pseudomembranous colitis.
Pseudomembranous colitis has been reported with the use of SUPRAX and other broadspectrum antibi otics (including macrolides, semisynthetic penicillins, and cephalosporins); therefore, it is import antto consi der this diagnosis in pati ents who develop diarrhea in association with the use of antibiotics. Symptoms of pseudomembranous colitis may occur during or after antibiotic treatm entand may range in seve rity from mild to lifethreatening. Mild cases of pseudomembranous colitis usuall y respond to drug discontinuation aione. In moderate to severe cases, management shouid includefluids, electrolytes, and protein suppieme ntation. If the colitis does not improve after the drug has been discontinued, or if the symptomsare severe, oral vancomycin is the drug of choice for antibiotic-associated pseudome mbranous coiitis produced by C. difficile. Other causes of coli tis should be excluded.
PRECAUTIONS:
General: The possibili ty of the emergence of resistant organisms which might result in overgrow1h should be kept in mind, particul arl y during prolongedtreatment. In such use, careful obse rvation of the patient is esse ntial. Take appropriate measures if superinfection occurs during therapy. Adjust the SUPRAX dose in patients with renal impairment aswell asthose undergoingconti nuous ambulatoryperitoneal dial ysis (CAPD) and hemodi al ysis (HD). Monit or patients on dial ysis carefully. (See DOSAGE AND ADMIN· ISTRATION in full Prescribing Inform ation.) Prescribe SUPRAX with caution in individuals with a hi story of gastrointestinal (GI) disease, particularl y colitis. Drug Interaclions: Carbamazepine-Elevated carbamazepine level s have been reported when SUPRAX is administered concomi tantly. Drug monitoring may be of assistance in detectingalterat ions in carbamazepine plasma concentrations. Drug/Laboratory Test Interaclions: A faisepositive reac tion for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide. The administration of SUPRAX may result in a fal se-positive reaction for glucose in the urine using Clinitest" **, Benedi ct's solution, or Fehling's solution. It is reco mmended that glucose tests based on enzymatic glucose oxidase reactions (such asClinistix"** or Tes-Tape'" ") be used. A fal se-positive direct Coombs test has beenreported duringtreatment with other cephalosporin antibiotics; it should berecognizedthat a positive Coombs test may bedueto the drug. Carcinogenesis, Mutagenesis, Impairment of Fertility: Lifetime studies in animais to evaluate carcinogenic potentiai have not been conducted. SUPRAX did not cause pointmutat ionsin bacteria or mammalian cells, DNA damage, or chromosome damage in vitro and did not exhibit clastogenic potential in vivo in the mouse micronucleus test. In rats, fertilit y and reproductive performance we re not affecte d by cefixi me at doses upto 125 times the adult therapeutic dose. Usage in Pregnancy: Pregnancy Category B. Reprodu ction studies have been performed in miceand rats at doses up to 400 times the human dose and have reveaied no evidence of harm to the fetus due to SUPRAX. There are no adequate and well-controlled studies in pregnant wome n. This drug should be used during pregnancy only if ciearly needed . Labor and Delivery: SUPRAX has not beenstudied for use during labor and del ivery. Give oniy if ciearly needed. Nursing Mothers: It is not known whethe r SUPRAX is excreted in human mil k. Consider discont inuing nursing temporarily during treatment. Pediatric Use: Safety and effectiveness of SUPRAX in chi ldren aged less thansix months old have not beenestablished. The inci dence of GI adve rse reactions, including diarrhea and loose stools, in ped iatri c patient s receiving the suspe nsi on, was comparableto theincidence seen in adult pati ents recei vingtablets.
ADVERSE REACTIONS:
Most adverse reactions observed in clinical trials were of a mil d andtransientnature. Five percentof patients in the U.S.trial s discontinued the rapybecause of drug-related adve rse reactions.The most common adve rse reactions in U.S. triai s of thetabi et formulation were Gi eve nts, which were reported in 30% of adult patients on ei ther the BIDor the QD regimen. Clinically mil d GI side effects occurred in 20%of all patients, moderate events in 9%, and seve re adve rse reactions occurred in 2% of all patients. Indi vidual event rates included diarrhea 16%, loose or frequent stools 6%,abdominal pain 3%, nausea 7%, dyspe psia 3%, and flatuience 4%. The incidence of GI adverse reacti ons, including diarrhea and loose stools, in pediatric patients receivi ng the suspension was comparable to that see n in adult patients receiving tablets. Symptoms usually respond ed to symptomatic therapy or ceased when SUPRAX was discontinued. Seve ral patients developed severe diarrhea and/or docum ent ed pseudomembranous coiitis, and a few required hospitali zation. \
The following adve rse reactions have been reported following the use of S U P~AX . Incidence rates we re less than 1 in 50 (less than 2%), except as noted above for GI events. GI (see above): Di arrhea, loose stools, abdom inai pain, dyspepsia, nausea, and vomiting. Seve ral cases of docume nted pseudomemb ranous colitis were identified during the studies; onset of sym ptoms may occur during or after therapy. Frequency in Hertz (Hz) Figure 1A . Initial audiogram of patient #1. Note the moderate sloping sensorineural hearing loss at 8,000 Hz.
thresholds were 10 dB in both ears, and his speech discrimination thresholds were 100% at 40 dB in both ears. There was no change in either of these threshold s at any point during this patient's treatment. He was managed conservatively with bed rest and head elevation, and he was told to avoid strenuous activity . His hearing loss in the left ear stabilized at 20 dB at 8,000 Hz, and it had remained at this level 3 years postinjury. The man resumed diving 3 months after the injury and completed more than 100 dives with no further problem s (figure lB) . Figure 1B . Recovery audiogram for patient #1 after 5 days of conservative management. His hearing still remained stable after 21 months.
Case 3
A 31-year-old woman developed otalgia while diving to 50 feet. She subsequently completed a second, shallower dive, after which her ear pain worsened and she experienced right -sided hearing loss.
The patient came to the ENT clinic 7 days later. She denied aural fullness or tinnitus. She initially denied vertigo or dizziness , but did complain of imbalance. The physical examination was unremarkable. The tympanic membrane was intact, mobile, and without an air-flu id level. There was no nystagmus, her fistula test was equivocal, and an audiogram revealed a mild to moderate sensorineural hearing loss on the right and a mild high-frequency sensorineural hearing loss on the left ( figure 3A) . The woman' s speech reception thresholds were 20 dB and 5 dB and her speech discrimination thresholds were 100% at 60 dB and 45 dB in the right and left ears ; respectively .
She was managed conservatively with bed rest and advised to avoid strenuous activitie s and to use a stool softener, but her improvement was minimal. In response to her continued symptoms of imbalance, vestibular testing was performed. It revealed a right-sided weaknes s. The patient underwent an exploratory tympanotomy, with patching of the round and oval windows (fluid was observed leaking from the round window). The patient reported a resolution of her diseq uilibrium on postoperative day 1 and an improvement of her hearing within 2 weeks of Case 2 A 28-year-old black man was examined after a dive to 35 feet, during which he reported some difficulty in initially clearing his ears. Upon surfac ing, he complained of diminished hearing in the left ear, imbalance without true vertigo , mild nausea with emesis, and head ache . He denied any sensation of aural fullne ss, otalgia, or tinnitus .
Physical examination revealed an intact, injected tympanic membrane without an airfluid level. There was no nystagmus , and the remainder of the exam was unremarkable. An audiogram revealed a mild unilateral sensorineural hearing loss on the left (figure 2A). He had speech recept ion thre sholds of 5 dB and 10 dB and speech discrimination thresholds of 100% at 45 dB and 50 dB in the right and left ears, respectively. He was managed conservatively with 5 days of bed rest and advised to avoid all strenuous activities and to use a stool softener. Seven days later , his imbalance had resolved and his hearing had improved (figure 2B).
Six weeks following his initia l injury , the patient reappeared at the clinic after serving subm arine duty . He again complained of diminished hearing and imbalance, but not vertigo. Examination at this time was unremarkable, with no nystagmus , intact tympanic membranes without an airfluid level, and a negative fistula test. An audiogram again revealed a sensorineural hearing loss on the left, but this time it was in the moderate to severe range (figure 2C).
The patient subsequently unde rwent an explo ratory tympanotomy on the left in response to worsening vestibular symptoms. The procedure revealed that fluid was leaking from the oval window . The window was patched with temporalis fascia , as was the round window . A follow-up audiogram 1 month postoperatively revealed that the sensorineural hearing loss on the left had improved to the mild to moderate range . He also experienced a complete resolution of his vestibular symptoms. His hearing has remained stable (figure 2D) . He has not resumed diving. 
Hearing Level in 20 Dec ibels (dB)~5 0 60 70 80 90 100 110 Figure 2A . Initial injury audiogram of patient #2. He presented with mild vestibular complaints in addition to this mild high-frequency sensorineural hearing loss. Figure 2D . A 1-month postoperative audiogram on patient #2 revealed a mild to moderate sensorineural hearing loss on the left. A perilymphatic fistula of the oval window was repaired at surgery. Figure 2C . Initial reinjury audiogram of patient #2. Note the sloping , moderate to severe sensorineural hearing loss on the left. This injury occurred 6 weeks after the previous injury . surgery. One month postoperatively, her speec h rece ption and speech discrimin ation thres holds on the rig ht had imp roved to 10 dB and 100% at 50 dB (fig ure 3B). Th e pa tie nt has discont inued spo rt diving.
Discussion
Barotraum a refers to damage to the tissues as a res ult of cha nges in gas vo lume in an enclosed space (divers ca ll it "the sq ueeze") . Typ ically, divers equa lize the pressure wit hi n the middle ear cavity wi th that of the externa l enviro nment by swallowing or per forming Valsalva ' s man eu ver during their descen t. At sea level, the pressure of the externa l env iro nment , middl e ear, cereb rospinal fluid, and inner ear are equa l to 760 mm Hg. When a diver fai ls to eq ua lize duri ng descent, the pressure differential bet ween the nasoph arynx and the middle ear rises qu ickly. At a depth of2.6 fee t, the different ial is 60 mm Hg. At 3.9 fee t of depth , the pressure differenti al increases to 90 mm Hg, and the eustachia n tub e may "loc k," whic h renders the diver unable to equa lize the pressur e in the ea rs."
Ba rotr auma ca n occur to both the m iddle and inner ear sim ultaneo usly or se pa rate ly. Wh en it is co nfine d to the middle ear, patients ex perience sy mptoms of ota lgia and hearing loss. Ph ysical examination wi ll reveal vascular inj ection or hemorrhage int o the tympani c membrane, a perforated ty mpa nic membran e, and/or an air-fl uid level in the mesotymp an um. Au dio me try will ex hi bit a co nducti ve hearing loss. Treatment is symptoma tic . Us ua lly , sy mptoms resolve and ph ysical fin di ngs normali ze in a matt er of days or weeks. Once thi s occ urs , sc uba di ving can be resumed .
Th e symp to ms of inner ear ba rotrauma include varying lev el s of hearing loss, tinni tus, and dizzin ess. A no ther co mmon sy mptom is aura l fullness. Becau se midd le ear barotrau ma an d inner ear barot rau m a ca n coexist or ca n be si milar in their presen tation , an air and bon e co nduct ion aud iogra m is 'requ ired to acc urately differen tiate between them." T he di agnosis of the pa rtic ula r type of inn er ear barot rau ma is ty pica lly made in retros pect, afte r treatment has been ren dered and recovery audiog rams are ana lyzed.
Hemorrhage, Tears, and Fistulas
It is hypoth esi zed that inner ear barot rau ma , is ca use d by o ne of three mech an ism s: hernorrhage within th e inne r ear, a tear in the lab y- rinthin e memb rane, or a peril ymph atic fistula through the oval or round window. 5 Simmons first proposed that sudden hearing loss could be caused by cochlear memb rane breaks." Later, GoodhiII sugges ted that irregular inner ear fluid dynamics might be a cau se of window fistula in abrupt and inten se inner ear pressure changes.'
The literature contains histologic documentation of inner ear hemorrh age and cochlear membrane tear s, in addition to several repo rts of inner ear fistulas after barotrauma.v" Howeve r, Becker and PareIl feel that this classification is a clinical one due to the lack of definiti ve supporting data.5.1 2.13 They make mention of unpubli shed data on the evaluation of the temp oral bone s of 20 patient s who died whil e scuba diving, and they note.that while some intracochlea r hemorr hages were found, there was no evidence of memb rane tears.
These three inner ear injuri es may occur separately or in co mbination with one another . In fact, Simm ons previously proposed that concomit ant cochlear membrane
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• thatif therapy withoral levofioxacinisinitiated.then (1)antacidscontainingmagnesium, oraluminum,aswellassucratfate,metal cations such asiron , and mul tivi taminpreparations wi thzinc orVidex®, (Di danosi ne), cnewableJbutleredtabletsorthepedi atricpowder tor ora l solution shouldbetakenal least two hours beforeor1\'/0hou rsatter levonoxacin administration. (See Drug Inter actions ): and(2)ora l levofioxacincan betakenwithoutregardtomeal s. tube may resu lt in a violent movement of the stapes, precipitating shearing forces in the inner ear and resulting in hemorrhage, intracoc hlear membrane tears , or round-or oval-window perilymphatic fistulas. These mechanisms of injury ca n be exp losive and impl osive. Intracochl ear hemorrhage is usually associated with middle ear baro trauma. The vestibul ar sympto ms, if any, are bri ef, an d audiography will reveal a diffuse, mild to severe sensorineural hearing loss, sloping to the high frequencies. The audiogram will stabilize or return to normal over the ensuing days to month s. These patients are treated with bed rest and eleva tio n of the head, and they are instructed not to strain, sneeze , blow theirnose, or perfor m Valsalva' s maneuver. If there is no deterioration of cochleovestibular symptoms, they are allowe d to return to nonstrenuous activity after 10 days and to a full resumption of normal activity at 6 weeks. Scuba diving is permitted after 3 month s if the patient exhibits normal hearing in the speech range, no ves tibular deficit, and no other
ECM MIRROR WARMER MEETING THE NEEDS OF DOCTORS IN CLINIC APPLICATIONS WARMING MIRRORS TO PREVENT FOGGING
The unit is fully insulated and automatically sets itself to operating tempera ture. The ECM mirror warmer offers these advantages: 
Decomp ression Sickness
In all cases of barotrauma, it is important that the phy sici an determine the patient' s "dive profile" to help determine whether or not the patient is suffering from decompression sickness. The dive profile refers to the length of time that a diver is able to stay at vario us depths without needin g to decompress. Decompression sickness is cau sed by the form ation of nitrogen bubbles in tissues and organs. As a diver descends, the increase in water pres sure leads to an incre ase in the partial pressures of nitrogen and oxygen in tissue and fluid . Whi le oxygen is con stantly metabolized, nitrogen is inert , and during ascent, nitrogen escapes from the dissolved state . When this occurs at a rate that exceeds the lungs' ability to expel nitrogen, nitrogen bubbles form .
A decompression dive is one in which the diver must stay at variou s depths for cert ain interv als of time in orde r to "o ff gas" the nitrogen in his body . Mo st recreational scuba diving is of the nondecompression type. Typically, decompression sickness manifests as central nervous system and coch leove stibular symptoms, alt hough isolated inner ear decompression sickness has also been reported in the literature.I I The cochleovestibular man ifestations are the result of the form ation of nitrou s gas bubbles in the otic fluid and the microvessel s of the ear. A patient who is suffering from decompression sickness requires immediate treatment in a hyperbaric chamber.
The resumption of scuba diving by the patient with an intracochlear hemorrhage in this report (patient # I ) lends further credence to the theory that patients who suffer inner ear barotrauma may resume .the sport and that current recommendation s against diving may be unneces-similar to those of an inner ear hemo rrha ge , However, a locali zed persistent loss at the area of membrane rupture may be seen on the reco very audio gram .' Patient s with this type of injury are treated similarly to those with intracochlear hemorrhage. None of the thre e patients described in this report is believed to have suffered a membrane tear.
A perilymphatic fistul a may pres ent with a mild highfrequency sensorineural hearing loss or with significant cochleovestibular symptoms. These patients are also treated with bed rest and avoidance of strenuous act ivities. Howe ver, if there is any further loss of hearing or if significant vestibu lar symptoms persist during the first 5 to 10 days postinjury, an exploratory tympanotomy with patching of the round and oval windows is indicated. Further diving is discouraged if. a fistul a is found or if there is a significant residual hear ing or vestibular deficit.' Patients #2 and #3 in this report were found to have an inner ear fist ula. Patient #2 had a residual hearing loss, while patient #3 has a complete resolution of all cochleovestibular symptoms . Both patients were advi sed not to resume scuba diving. Rat Hepatocyte DNA Repair Assay Micronucleus Test (Mice) Dominant LethalTest (Mice) Long-term carcinogenicity studies in mice and rats have been completed for ciprotlexacin. After dail y oral doses of 750 mg/kg(mice) and 250mg/kg (rats) wereadministered for upto 2 years, there was no evidence that ciprofloxaci n hadany carcinogenicor tumorigenic effects in thesespecies. Nolong term studiesof CIPRO' HC OTIC suspension have beenperformed to evaluatecarcinogenic potential. Fertilit y studiesperformedin rats at oral doses of ciprofloxacin up to 100 mg/kg/day reveal ed no evidence of impairment. This would beover 1000 times the maximum recommended clinical dose of ototoplcal ciprotloxacin based upon body surface area, assuming total absorption of clprouoxacln from the ear of a pat ient treatedwith CIPRO' HCOTICtwice perday. Long term studies have not beenperformedto evaluatethe carcinogenic potentialor theeffect on fertili ty of topical hydrocortisone. Mutagenicity studieswith hydrocortisonewerenegative. . Pregnancy: TeratogenicEff ects. Pregnancy Category C:
Reproduction studies have beenperformed in rats andmice using oral doses of upto 100 mg/kg and IVdoses upto 30 mg/kg and have reveal edno evidence of harmto the fetusasa resul t of ciprofloxacin. Inrabbit s, clpronoxacln(30 and100 mglkg orally)producedgastrointestinaldisturbances resulting in maternal weight loss and an increased incidence of abortion, but no teratogenicitywas observed at either dose. After intravenous administration of doses upto20mglkg, no maternal toxici ty was produced in the rabbit, and no embryotoxicity or teratoge nicity was observed.
Corticosteroidsaregen erally teratogeni c in laboratoryanimals when admi nistered systemically at rel atively low dosage levels. The more potent corticosteroidshave been shown to beteratogenic afterdermal application in laboratory ani mals. Animal reproductionstudieshavenotbeenconductedwithCIPRO' HCOTIC. No adequate andwell controlled studies have beenperformed in pregnant women. Caution should be exercised when CIPRO' HCOTICis used by a pregnant woman. Nursing Mothers: Ciprotloxacin is excreted in humanmilk withsystemic use. It is not known whetherciprofloxacin is excreted in humanmilk following topi cal otic administrati on. Because of the pot ential for seriousadverse reactions in nur sing infants, a decision should be made whet her to discontinue nursing or to discontinue the drug, takinginto account the importance of thedrug to the mother. Pediatric use: The safety and efficacy of CI PRO' HC OTIC have been established in ped iat ric patients 2 years and older (131 pati ent s) in adequate and well-controlled clini cal trials. Althoughno dataareavailable onpatients less thanage 2years, thereare no known safety concerns or differences in the disease process in this populationwhich wouldpreclude use of this product in patients oneyear and older. See OOSAGE ANO AO MINISTRATIO N.
AOVERSEREACTIONS
InPhase3clinical trial s, atotal of 564 pat ients weretreatedwithCIPRO' HCOTI C.Adverse events withat least remoterel ationshipto treatment included headache(1.2%)and prur itus (0.4%). The following treatment-related adverse events were each reported in a single patient: mig raine, hypesthesi a, paresthesi a, fungaldermatitis, cough, rash, urticaria, andalopecia. sarily restrictive . Parell and Becker reported a series of 20 divers who experienced inner ear barotraum a but who have co ntinued to dive without sequelae afte r their inj uries were treated .13 This series included patient s who had suffered all three types of inner ear injur ies; 4 pati ent s who had fistulas have completed between 8 and 400 dives; 10 patient s who had hemorrhages have com pleted between 60 and more than 2,000 dives; and 6 who had membrane tears have completed from 8 to I,OOO-plus dives. None of these patient s experienced any further injur y to their previously traumatized inner ear. Moreover, even patient s with per ilymphatic fistulas, as reported by Parell and Becker, have been able to cont inue diving without further injury ." Howe ver, furth er study of inne r ear barotr auma needs to be performed befor e any definiti ve recommendation s can be made. In the meantime, patient s who insist on resuming scuba diving after an inner ear bar otrauma should be co unseled not to dive within 2 weeks of any upp er respir atory illness and to descend in a fee t-firs t position to avoid congestion of the eustachian tub e and subsequent difficulty in equalizing pressure in their ears. Also, these patients should be rein struct ed on the various maneu vers to equalize their ears and to abort any dive if they encounter difficulty clearing their ears.
